Pharmaceutical

Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood of Approval

Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma.

Jan 9, 2024 - 18:00
Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood of Approval
Subasumstat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Relapsed Multiple Myeloma.
Read the original article

Tags:

Previous Article

HH-006 by Huahui Health for Hepatitis D: Likelihood of Approval

Next Article

AUR-101 by Aurigene Oncology for Psoriatic Arthritis: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Researchers devise new strategies to overcome a key CRISPR flaw

STAT+: Researchers devise new strategies to overcome a ...

Mar 22, 2023

Opinion: Where do we go from here on digital therapeutics?

Opinion: Where do we go from here on digital therapeutics?

Feb 1, 2024

STAT+: Novocure’s electric fields device prolongs survival in lung cancer, but doubts remain

STAT+: Novocure’s electric fields device prolongs survi...

Jun 6, 2023